Introduction
Methods
Results of Literature Search
Pharmacology
Pharmacokinetics
Pharmacodynamics
Antipyresis by Paracetamol: Pharmacology-Based Practical Implications
Analgesia by Paracetamol: Pharmacology-Based Practical Implications
Clinical Management of Fever with Paracetamol
Clinical Trial Data
Study (design; setting) | Patients (N; age range) | Treatments (n) | Regimen | Efficacy endpoint | Efficacy results (PARA vs. comparator) | Adverse events (PARA vs. comparator) |
---|---|---|---|---|---|---|
Versus NSAIDs | ||||||
Autret-Leca et al. [34]. (R, DB [1st dose]/OL [3 days], MC, PG; GP) | Fever (304; 0.25–12 years) | PARA 15 mg/kg (150) IBU 10 mg/kg (151) | Repeat dose for 3 days | AUC0-6 h
| Mean AUC0–6 h
−7.66 vs. −7.77 °C/min (P = 0.82) | Any AE 10.6% vs. 11.2% Infections 4.6% vs. 3.3% GI disorders 2.6% vs. 2.6% Respiratory disorders 2.6% vs. 2.6% |
Carabano et al. [35]. (PG; NR) | Fever, ≥38 °C (166; NR) | PARA 15 mg/kg (80) IBU 7 mg/kg (86) | Single dose | Change in temperature after drug administration | At 1 h 37.80 vs. 37.66 °C (P = 0.22) At 2 h 37.29 vs. 37.09 °C (P = 0.14) At 3 h 37.28 vs. 37.12 °C (P = 0.64) At 4 h 37.46 vs. 37.40 °C (P = 0.72) | NR |
Celebi et al. [59]. (R, PG; ED) | Fever (301; 1–14 years) | PARA 15 mg/kg (112) IBU 10 mg/kg (84) KETO 0.5 mg/kg (105) | Repeat dose for 48 h | Change in temperature after drug administration | At 30 min 38.4 vs. 38.5 vs. 38.4 °C At 60 min 38.0 vs. 38.1 vs. 37.9 °C At 120 min 37.7 vs. 37.7 vs. 37.6 °C At 4–6 h 37.5 vs. 37.4 vs. 37.3 °C | Early (< 6 h) vomiting 3.8% vs. 9.6% vs. 13.5% Late (6–48 h) vomiting 1.3% vs. 5.8% vs. 2.7% |
PITCH [60]. (R, SB, MC, PG; OP) | Fever, ≥37.8 °C and ≤41.0 °C (156; 0.5–6 years) | PARA 15 mg/kga (52) IBU 10 mg/kgb (52) PARA + IBU (52) | Repeat dose for 48 h | Time without fever in the first 4 h | Time without fever in the first 4 h 219 vs. 211 vs. 202 min Time without fever in the first 24 h 1078 vs. 1029 vs. 1051 min | Diarrhea 19.2% vs. 17.3% vs. 23.1% Vomiting 11.5% vs. 5.8% vs. 3.8% Rash 3.8% vs. 3.8% vs. 1.9% |
Wong et al. [40]. (R, DB, MC, PG; NR) | Fever, ≥ 37.8 °C and ≤ 40.5 °C (628; 0.5–6 years) | PARA 12 mg/kgc (210) DIPYR 15 mg/kg (209) IBU 5/10 mg/kgd (209) | Single dose | Patients with a temperature reduction of ≥1.5 °C | Temperature reduction of ≥1.5 °C 77% vs. 86% vs. 83% Time to temperature reduction of ≥1.5 °C 109 vs. 103 vs. 120 min Normal (≤37.5 °C) temperature 68% vs. 82% vs. 78% (both P = 0.004 vs. PARA) | Drug-related AEs 15% vs. 17% vs. 27% Vomiting 3.8% vs. 4.3% vs. 2.9% Diarrhea 2.4% vs. 1.4% vs. 1.4% |
Versus PL | ||||||
Gupta et al. [38]. (R, DB, PC; tertiary care) | Fever, ≥ 37.6 °C and ≤ 40.5 °C (210; 0.5–6 years) | PARA 15 mg/kg (103) PL (107) | Single dose | Fever clearance time [time to normal (≤37.5 °C) temperature] | Median fever clearance time 32 vs. 36 h (P = 0.23) | AE in first 6 h 8.7% vs. 0% |
Kramer et al. [61]. (R, DB, PC; home) | Fever, ≥ 38 °C and < 41 °C (225; 0.5–6 years) | PARA 10–15 mg/kg (123) PL (102) | Multiple dose q4 h | Duration of fever | Mean duration of fever 34.7 vs. 36.1 h | NR |
Parenteral PARA (i.e., PROP) | ||||||
Reymond et al. [84]. (Two studies; R, OL, PG; hospital) | Fever (10/24; NR) | Study 1 PROP 30 mg/kg (5) ASA 15 mg/kg (5) Study 2 PROP 30 mg/kg (11) PROP 15 mg/kg (13) | Single dose | Change in temperature | Study 1: change in temperature −1.99 vs. −2.31 °C Study 2: change in temperature −1.79 vs. −2.11 °C | Burning sensation during PROP infusion in 45% of patients |
Drug-dosage comparison | ||||||
Treluyer et al. [36]. (R, DB, PG; NR) | Fever, 39–40.5 °C (121; 0.33–9 years) | PARA 30 mg/kg LD (62) PARA 15 mg/kg MD (59) | Single dose | Rectal temperature | Time to rectal temperature <38.5 °C 110.7 vs. 139.4 min (P = 0.05) | Any AE 9.7 vs. 8.5% |
Clinical Management of Pain with Paracetamol
Clinical Trial Data
Study (design; setting) | Patients (N; age range) | Treatments (n) | Regimen | Efficacy endpoint | Efficacy results (PARA vs. comparator) | Adverse events (PARA vs. comparator) |
---|---|---|---|---|---|---|
For pain | ||||||
Clark et al. [66]. (R, PG; ED) | MSK trauma (336; 6–17 years) | PARA 15 mg/kg (112) IBU 10 mg/kg (112) COD 1 mg/kg (112) | Single dose | Change in pain VAS at 60 min | Change in pain VAS at 60 min: –12 vs. –24 vs. –11 (both P ≤ 0.001 vs. IBU) | Any AE: 7.7% vs. 10.9% vs. 16.2% |
Cukiernik et al. [70]. (R, DB, PG; OP) | Soft tissue injuries to the ankle (77; 8–14 years) | PARA 15 mg/kg (36) NAP 5 mg/kg (41) | 5 days | Change in disability and pain VAS at day 7 | Change in disability VAS at day 7: From 7.4 to 1.0 vs. from 7.2 to 1.4 (P = 0.21) Change in pain VAS at day 7: From 6.4 to 0.5 vs. from 6.8 to 0.7 (P = 0.21) | Any AE: 16.7% vs. 9.8% |
Mahgoobifard et al. [68]. (R, DB, PG, PC; post-op) | Tonsillectomy (60; 4–12 years) | PARA 15 mg/kg (18) IBU 10 mg/kg (21) PL (21) | Single dose | Post-op pain (CHEOPS) | Post-op CHEOPS score: 7.05 vs. 8.14 vs. 8.36 (both p = 0.001) | NR |
Ruperto et al. [69]. (R, DB/OL, PC; OP) | Pharyngotonsillitis (97; 6–12 years) | PARA 12 mg/kga (34) KETO 40 mgb (33) PL (32) | Single dose | Child-reported SPID | Difference in child-reported SPID: PARA vs. PL (P < 0.05) PARA vs. KETO (NS) | No serious AEs reported |
Salmassian et al. [39]. (R, OL, PG; dental surgery) | Orthodontic tooth movement (60; 12–18 years) | PARA 600 mg (21) IBU 400 mg (19) PL (20) | Multiple doses | Pain VAS at peak pain after placement (19 h) | Mean VAS at 19 h: 3.75 vs. 4.79 vs. 5.23 | NR |
Shepherd et al. [65]. (R, PG; ED) | Acute limb fractures (72; 5–14 years) | PARA 15 mg/kgc (43) IBU 10 mg/kgd (29) | 48 h | Child-reported pain scores using ‘Faces’ pain scale | Mean pain score: 2.8 vs. 2.7 (P = 0.73) | No AEs with PARA IBU reported vomiting (2), tiredness (1) and dizziness (1) |
For migraine | ||||||
Hamalainen et al. [67]. (R, DB, CO, PC; OP) | Migraine (88; 4–15.8 years) | PARA 15 mg/kg IBU 10 mg/kg PL | Single dose | Reduction in severe or moderate headache | Reduction in severe or moderate headache: 54% vs. 68% vs. 37% | Any AE: 4.8% vs. 9.9% vs. 11.1% |